Out of the 204 patients with invasive breast carcinoma we surveyd, 123 (60.3%) were luminal A; 17 (8.3%), luminal B; 31 (15.2%), basal-like; 17 (8.3%), HER2-overexpreessing; and 16 (7.8%), unclassified (Figure 1). This evidence concerns the gene ERBB2 and invasive breast carcinoma.